司库奇尤单抗治疗儿童中重度斑块状银屑病3期研究24周结果
该3期开放标签随机多中心研究评估两种司库奇尤单抗剂量方案(低剂量75/75/150 mg;高剂量75/150/300 mg)在6-<18岁中重度斑块状银屑病患者中的疗效与安全性。第12周时两剂量组PASI-75/90和IGA 0/1应答均优于历史安慰剂,低剂量与高剂量组IGA 0/1应答率分别为78.6%和83.3%,PASI-90分别为69%和76.2%,PASI-75均为92.9%;司库奇尤单抗方案有效且耐受性良好。
要点
- 两种司库奇尤单抗剂量方案在第12周均优于历史安慰剂。
- 第12周低剂量与高剂量组PASI-75应答率均为92.9%。
- 研究为开放标签设计且无对照组,需注意解读局限性。
核心结论
- 司库奇尤单抗两种剂量方案在儿童中重度斑块状银屑病患者中有效且耐受性良好。
研究设计与样本
- 3期开放标签随机多中心研究(NCT03668613),纳入6-<18岁中重度斑块状银屑病患者,按体重(<25 kg、25至<50 kg、≥50 kg)和疾病严重程度(中度、重度)分层随机分配至低剂量(75/75/150 mg)或高剂量(75/150/300 mg)司库奇尤单抗方案。
主要发现
- 第12周时两种司库奇尤单抗剂量在PASI-75/90和IGA 0/1应答方面均优于历史安慰剂。
- 低剂量或高剂量司库奇尤单抗对比历史安慰剂获得阳性治疗效应(即对数比值比>0)的估计概率为1(即100%)。
- 第12周低剂量组和高剂量组IGA 0/1应答率分别为78.6%和83.3%。
- 第12周低剂量组和高剂量组PASI-90应答率分别为69%和76.2%。
- 第12周两种剂量的PASI-75应答率均为92.9%。
临床怎么用
- 对于6-<18岁中重度斑块状银屑病患者,可考虑按体重分层使用司库奇尤单抗低剂量或高剂量方案。
局限性
- 本研究为开放标签设计,无对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Psoriasis affects 0.13%-2.1% of children and adolescents. Despite a high unmet need, the current treatment options approved for pediatric psoriasis are limited. OBJECTIVE: To evaluate the efficacy and safety of 2 secukinumab dosage regimens (low dose: 75/75/150 mg; high dose: 75/150/300 mg) stratified and randomized by weight (<25 kg, 25 to <50 kg, ≥50 kg) and disease severity (moderate, severe) in pediatric patients aged 6-<18 years with moderate to severe plaque psoriasis. METHODS: This is a phase 3, open-label, randomized, multicenter study (NCT03668613). RESULTS: Both secukinumab doses were superior to historical placebo with respect to psoriasis area and severity index (PASI)-75/90 and investigator global assessment 0/1 responses at week 12. The estimated probability of a positive treatment effect (ie, log odds ratio > 0) for low- or high-dose secukinumab compared to historical placebo is 1 (ie, 100%). For the low and high doses at week 12, the investigator global assessment 0/1 response rates were 78.6% and 83.3%, respectively, and the PASI-90 response rates were 69% and 76.2%, respectively. The PASI-75 response rate was 92.9% for both the doses. LIMITATIONS: This is an open-label study design without a control arm. CONCLUSION: Secukinumab dosing regimens were efficacious and well tolerated in pediatric patients with moderate to severe plaque psoriasis.
引用
- Magnolo N, Kingo K, Laquer V, et al. A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 2021. PMID: 34555481. doi:10.1016/j.jaad.2021.08.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。